|
2026 Journal Article Large-scale testing of antimicrobial lethality at single-cell resolution predicts mycobacterial infection outcomesJovanovic, Alexander, Bright, Frederick K., Sadeghi, Ahmad, Wicki, Basil, Caño Muñiz, Santiago E., Giannini, Greta C., Toprak, Sara, Sauteur, Loïc, Rodoni, Anna, Wüst, Andreas, Lupien, Andréanne, Borrell, Sonia, Grogono, Dorothy M., Wheeler, Nicole E., Dehio, Philippe, Nemeth, Johannes, Pargger, Hans, Thomson, Rachel, Bell, Scott C., Gagneux, Sebastien, Bryant, Josephine M., Peng, Tingying, Diacon, Andreas H., Floto, R. Andres, Abanto, Michael and Boeck, Lucas (2026). Large-scale testing of antimicrobial lethality at single-cell resolution predicts mycobacterial infection outcomes. Nature Microbiology. doi: 10.1038/s41564-025-02217-y |
|
2025 Journal Article Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guardEvans, Ieuan Edward Shepherd, Smith, Daniel, Henderson, Daniel, Riddles, Timothy, Masel, Philip, Moore, Vanessa, Burke, Andrew J., Thomson, Rachel M. and Reid, David W. (2025). Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard. BMJ Open Respiratory Research, 12 (1) e003204, e003204. doi: 10.1136/bmjresp-2025-003204 |
|
2025 Journal Article In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolatesPatterson-Fahy, Kirby, Carter, Robyn, Bell, Scott C., Evans, Ieuan E. S., Burke, Andrew John and Thomson, Rachel M. (2025). In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates. Journal of Antimicrobial Chemotherapy, 81 (1) dkaf441, 1-9. doi: 10.1093/jac/dkaf441 |
|
2025 Journal Article Consensus on Management of Refractory Nontuberculous Mycobacterial Pulmonary DiseaseMoreira-Sousa, Diana, Martins, Beatriz, Aguiar, Ana, Pinheiro, Marina, Akkerman, Onno, Aksamit, Timothy R, Aliberti, Stefano, Andrejak, Claire, Daley, Charles L., van Ingen, Jakko, Lange, Christoph, Lipman, Marc, Loebinger, Michael R, Jankovic Makek, Mateja, Morimoto, Kozo, Thomson, Rachel M., Wagner, Dirk, Winthrop, Kevin L., Yim, Jae-Joon and Duarte, Raquel (2025). Consensus on Management of Refractory Nontuberculous Mycobacterial Pulmonary Disease. European Respiratory Journal, 67 (1), 2500400. doi: 10.1183/13993003.00400-2025 |
|
2025 Journal Article The microbiome and gut–lung axis in nontuberculous mycobacterial pulmonary diseaseThompson, Ria N., Blumenthal, Antje, Morrison, Mark and Thomson, Rachel M. (2025). The microbiome and gut–lung axis in nontuberculous mycobacterial pulmonary disease. PLOS Pathogens, 21 (10) e1013603, e1013603. doi: 10.1371/journal.ppat.1013603 |
|
2025 Conference Publication Mycobacteria acquisition from potable water across the drinking water system in AustraliaRamsay, K., Smith, K., Duplancic, C., Taylor, S., Rogers, G., Wainwright, C., Thomson, R. and Bell, S. (2025). Mycobacteria acquisition from potable water across the drinking water system in Australia. 2025 North American Cystic Fibrosis Conference, Seattle, WA United States, 22-25 October 2025. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s1569-1993(25)01643-1 |
|
2025 Conference Publication The aetiology and epidemiology of nontuberculous mycobacteria (NTM) in Australians with cystic fibrosisDuplancic, C., Alene, K., Ballard, E., Thomson, R., Wainwright, C., Rogers, G., Clements, A., Floto, A., Bell, S. and O. NTM in CF Investigators (2025). The aetiology and epidemiology of nontuberculous mycobacteria (NTM) in Australians with cystic fibrosis. 2025 North American Cystic Fibrosis Conference, Seattle, WA United States, 22-25 October 2025. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s1569-1993(25)01654-6 |
|
2025 Conference Publication The changing face of cystic fibrosis research: challenges of multi-centre microbiology cohort studiesEvans, I., Duplancic, C., Kidd, T., Ballard, E., Thomson, R., Wainwright, C., Bell, S. and O. NTM in CF Investigators (2025). The changing face of cystic fibrosis research: challenges of multi-centre microbiology cohort studies. 2025 North American Cystic Fibrosis Conference, Seattle, WA United States, 22-25 October 2025. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s1569-1993(25)01642-x |
|
2025 Journal Article Finding the optimal regimen for Mycobacteroides abscessus treatment (FORMaT) in people with Mycobacteroides abscessus pulmonary disease: a multicentre, randomised, multi-arm, adaptive platform trialJong, Tiffany, Baird, Timothy, Barr, Helen Louise, Bell, Scott, Bigirumurame, Theophile, Brady, Kara, Burke, Andrew, Byrnes, Joshua, Caudri, Daan, Clark, Julia E., Coin, Lachlan J.M., Goh, Felicia, Grimwood, Keith, Hicks, Daniel, Jayawardana, Kaushala, Joshi, Sri, Lee, Katherine, Qvist, Tavs, Reid, David, Rice, Megan, Roberts, Jason A., Rogers, Geraint, Shackleton, Claire, Sly, Peter D., Smyth, Alan R., Stevens, Luke, Stockwell, Rebecca, Tarique, Abdullah, Taylor, Steven ... Wainwright, Claire (2025). Finding the optimal regimen for Mycobacteroides abscessus treatment (FORMaT) in people with Mycobacteroides abscessus pulmonary disease: a multicentre, randomised, multi-arm, adaptive platform trial. BMJ Open, 15 (9) e096188, 1-16. doi: 10.1136/bmjopen-2024-096188 |
|
2025 Journal Article The changing face of cystic fibrosis research: challenges of multi-centre microbiology cohort studiesEvans, Ieuan ES, Duplancic, Christine M, Kidd, Timothy A, Ballard, Emma L, Thomson, Rachel M, Wainwright, Claire E and Bell, Scott C (2025). The changing face of cystic fibrosis research: challenges of multi-centre microbiology cohort studies. Journal of Cystic Fibrosis, 24 (5), 903-908. doi: 10.1016/j.jcf.2025.07.002 |
|
2025 Journal Article Disinfectant and antibiotic resistance in Mycobacterium abscessus water isolatesPatterson-Fahy, Kirby, Carter, Robyn, Taylor, Steven L., Guo, Jianhua and Thomson, Rachel M. (2025). Disinfectant and antibiotic resistance in Mycobacterium abscessus water isolates. Microbiology Spectrum, 13 (7) e0337424, 1-12. doi: 10.1128/spectrum.03374-24 |
|
2025 Conference Publication Prevalence of nausea and vomiting and anti-emetic use in the tinding the optimal regimen for Mycobacterium abscessus treatment (Format) trialWainwright, C., Hicks, D., Rice, M., Jong, T., Joshi, S., Wang, X., Burke, A., Thomson, R., Grimwood, K., Bell, S. and Clark, J. (2025). Prevalence of nausea and vomiting and anti-emetic use in the tinding the optimal regimen for Mycobacterium abscessus treatment (Format) trial. 48th European Cystic Fibrosis Conference, Milan, Italy, 4-7 June 2025. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.jcf.2025.03.119 |
|
2025 Conference Publication Adverse events related to study drugs in finding the optimal regimen for Mycobacterium abscessus treatment (FORMaT) trialWainwright, C., Hicks, D., Rice, M., Jong, T., Gailer, N., Joshi, S., Wang, X., Burke, A., Thomson, R., Grimwood, K., Bell, S. and Clark, J. (2025). Adverse events related to study drugs in finding the optimal regimen for Mycobacterium abscessus treatment (FORMaT) trial. 48th European Cystic Fibrosis Conference, Milan, Italy, 4-7 June 2025. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.jcf.2025.03.118 |
|
2025 Journal Article World Bronchiectasis 2025—Inclusive Lungs, Diverse SolutionsThomson, Rachel Mary and Morgan, Lucy Catriona (2025). World Bronchiectasis 2025—Inclusive Lungs, Diverse Solutions. Respirology, 30 (7), 552-554. doi: 10.1111/resp.70063 |
|
2025 Conference Publication Prevalence of Nausea and Vomiting and Anti-emetic Use in the Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (FORMaT) TrialThomson, R., Hicks, D., Rice, M., Jong, T., Joshi, S., Wang, X., Burke, A.J., Grimwood, K., Bell, S., Clark, J. and Wainwright, C.E. (2025). Prevalence of Nausea and Vomiting and Anti-emetic Use in the Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (FORMaT) Trial. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. doi: 10.1164/ajrccm.2025.211.abstracts.a7277 |
|
2025 Conference Publication Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) TrialThomson, R., Hicks, D., Rice, M., Jong, T., Gailer, N., Joshi, S., Wang, X., Burke, A. J., Grimwood, K., Bell, S., Clark, J. and Wainwright, C. E. (2025). Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) Trial. 52nd Critical Care Congress of the Society of Critical Care Medicine (SCCM), San Francisco, CA United States, 21-24 January 2023. New York, NY United States: American Thoracic Society. |
|
2025 Conference Publication Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) TrialThomson, R., Hicks, D., Rice, M., Jong, T., Gailer, N., Joshi, S., Wang, X., Burke, A.J., Grimwood, K., Bell, S., Clark, J. and Wainwright, C.E. (2025). Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) Trial. ATS International Conference, San Francisco, CA, United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. doi: 10.1164/ajrccm.2025.211.abstracts.a7278 |
|
2025 Conference Publication Gut microbiome signatures discriminate nontuberculous mycobacterial pulmonary disease patients requiring treatment from those with stable diseaseThompson, R., Lim, Y., Goh, F., Blumenthal, A., Morrison, M. and Thomson, R. (2025). Gut microbiome signatures discriminate nontuberculous mycobacterial pulmonary disease patients requiring treatment from those with stable disease. ATS International Conference, San Francisco, CA USA, 16-21 May 2025. New York, NY USA: American Thoracic Society. |
|
2025 Conference Publication Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary DiseaseTwining, M., Kang, S., Riddles, T., Evans, I., Burke, A. J. and Thomson, R. (2025). Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary Disease. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. |
|
2025 Conference Publication Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary DiseaseTwining, M., Kang, S., Riddles, T., Evans, I., Burke, A.J. and Thomson, R. (2025). Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary Disease. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. doi: 10.1164/ajrccm.2025.211.abstracts.a5444 |
